Stock Quote

Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C

[PR Newswire] – NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ — AbbVie (ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company’s investigational, . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Submits New Drug Application to U.S. FDA for its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Similar Articles: Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14 AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.